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Abstract 
Background: Lowering the diagnostic threshold for troponin is controversial because it may 
disproportionately increase the diagnosis of myocardial infarction in patients without acute 
coronary syndrome. We assessed the impact of lowering the diagnostic threshold of troponin 
on the incidence, management and outcome of patients with type 2 myocardial infarction or 
myocardial injury. 
Methods: Consecutive patients with elevated plasma troponin I concentrations (≥50 ng/L; 
n=2,929) were classified as type 1 (50%) myocardial infarction, type 2 myocardial infarction 
or myocardial injury (48%) and type 3-5 myocardial infarction (2%) before and after lowering 
the diagnostic threshold from 200 to 50 ng/L with a sensitive assay. Event-free survival from 
death and recurrent myocardial infarction was recorded at one year. 
Results: Lowering the threshold increased the diagnosis of type 2 myocardial infarction or 
myocardial injury more than type 1 myocardial infarction (672 versus 257 additional patients, 
P<0.001). Patients with myocardial injury or type 2 myocardial infarction were at higher risk 
of death compared to type 1 myocardial infarction (37% versus 16%; RR 2.31, 95%CI 1.98-
2.69), but had fewer recurrent myocardial infarctions (4% versus 12%; RR 0.35, 0.26-0.49). 
In patients with troponin concentrations 50-199 ng/L, lowering the diagnostic threshold was 
associated with increased healthcare resource utilization (P<0.05) that reduced recurrent 
myocardial infarction and death for patients with type 1 myocardial infarction (31% versus 
20%; RR 0.64, 0.41-0.99), but not type 2 myocardial infarction or myocardial injury (36% 
versus 33%; RR 0.93, 0.75-1.15). 
Conclusion: Following implementation of a sensitive troponin assay, the incidence of type 2 
myocardial infarction or myocardial injury disproportionately increased and is now as 
frequent as type 1 myocardial infarction. Outcomes of patients with type 2 myocardial 
infarction or myocardial injury are poor and do not appear to be modifiable following 
reclassification despite substantial increases in healthcare resource utilization.   
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Introduction 
The Universal Definition of Myocardial Infarction proposes a classification for patients with 
myocardial infarction based on etiology in order to accommodate more sensitive markers of 
myocardial necrosis.1 The classification differentiates between type 1 myocardial infarction, 
due to thrombosis of an atherosclerotic plaque, and type 2 myocardial infarction due to an 
imbalance of myocardial blood supply and demand that may arise in many acute medical and 
surgical conditions. The expert consensus further defines evidence of myocardial necrosis in 
the absence of clinical evidence of myocardial ischemia as myocardial injury. Whilst this 
classification has been used in recent clinical trials to refine clinical outcomes2-4, type 2 
myocardial infarction and myocardial injury are difficult to distinguish or diagnose 
definitively, and the frequency in clinical practice and implications of these diagnoses are 
uncertain. 5,6 
 
Following improvements in assay performance, a sensitive troponin assay was introduced into 
our institution.7,8 The validation and subsequent implementation of this assay provided an 
opportunity to assess the impact of lowering the diagnostic threshold on the incidence, 
management and clinical outcome of patients with type 2 myocardial infarction and 
myocardial injury. 
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Methods 
Study population  
We identified consecutive patients admitted to our regional cardiac center (Royal Infirmary, 
Edinburgh, United Kingdom), with plasma cardiac troponin I concentrations ≥50 ng/L 
irrespective of clinical presentation during the validation and implementation of a 
contemporary sensitive troponin assay. We report a pre-specified analysis from a published 
cohort study evaluating the impact of implementation of a contemporary sensitive troponin 
assay on patients with suspected acute coronary syndrome.7 In this analysis we include all 
patients in whom troponin was measured as part of routine clinical care whether or not they 
presented with suspected acute coronary syndrome. 
 
Clinical characteristics as described previously7 including the primary presenting symptom, 
referral to specialist cardiology services, cardiac investigations, percutaneous or surgical 
coronary revascularization and the use of medical therapies were obtained through ‘TrakCare’ 
(InterSystems Corporation, Cambridge, MA, USA): an electronic patient record system used 
by all hospitals in National Health Service (NHS) Lothian, United Kingdom. Exclusion 
criteria included patients admitted for elective non-emergency procedures, patients resident 
outwith Lothian, and those incomplete hospital records.  
 
Troponin assay  
Plasma troponin I concentrations were measured using the ARCHITECTSTAT assays (Abbott 
Laboratories, Abbott Park, IL). The study was divided into two phases: validation and 
implementation. Whilst plasma troponin was measured using the reformulated sensitive assay 
throughout both phases, only concentrations above our previous diagnostic threshold (≥200 
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ng/L) were reported in the validation phase, whilst concentrations above the revised 
diagnostic threshold (≥50 ng/L) were reported during the implementation phase.7  
 
Classification of myocardial infarction 
Patients were classified as having a type 1 myocardial infarction when myocardial necrosis 
occurred in the context of an isolated presentation with suspected acute coronary syndrome 
with chest pain or evidence of myocardial ischemia on the electrocardiogram.1 Patients with 
symptoms and signs of myocardial ischemia on the electrocardiogram which were thought to 
be due to either increased oxygen demand or decreased supply (e.g. tachyarrhythmia, 
hypotension or anemia) and myocardial necrosis, were classified as having a type 2 
myocardial infarction. Myocardial injury was defined as evidence of myocardial necrosis in 
the absence of any clinical features of myocardial ischemia. Myocardial infarction presenting 
as a sudden unexpected cardiac death (type 3), following percutaneous coronary intervention 
(type 4) and coronary artery bypass grafting (type 5) were also defined. Each case was 
reviewed and classified independently by two cardiologists and any discrepancies resolved by 
consensus through indepth review of source data. Four hundred consecutive patients were 
classified by two internal medicine physicians to determine the generalisability of 
classification.  
 
Outcomes 
Clinical outcomes were identified using national and local population registries, the General 
Register of Scotland and TrakCare respectively. The primary outcomes were recurrent type 1 
myocardial infarction and all-cause mortality at one year. Recurrent myocardial infarction 
was defined as admission with chest pain or ST-segment deviation of ≥0.5 mm with evidence 
of myocardial necrosis using plasma troponin concentrations of ≥50 ng/L as the diagnostic 
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threshold. Secondary outcomes were coronary revascularization, stroke, gastrointestinal 
bleeding9 and length of stay. 
 
Statistical Analysis  
Summary clincial statistics were compared by type of myocardial infarction, and between 
implementation and validation phases using Chi-squared, Fisher’s exact, Students t- and 
Mann-Whitney U tests where appropriate. Agreement for the classification of myocardial 
infarction was estimated using Cohen’s kappa. Cox regression models were used to explore 
competing risks. Cause specific hazard ratios were estimated for type 1 versus 2 myocardial 
infarction and myocardial injury for time to death and time to recurrent myocardial infarction 
seperately with adjustment for age and sex. Analyses were performed in SPSS (IBM Version 
20.0.0, USA) and R (Version 2.14.2, Austria).  
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Results 
We identified 2,929 patients with a peak plasma troponin concentration ≥50 ng/L of whom  
764 met the exclusion criteria (eFigure); 1,171 (54%) were classified as type 1 myocardial 
infarction, 429 (20%) as type 2 myocardial infarction, 522 (24%) as myocardial injury, and 43 
(2%) as type 3-5 myocardial infarction. There was excellent agreement between cardiologists 
(κ=0.92, 95% CI 0.89-0.95) and internal medicine physicians (κ=0.87, 95% CI 0.82-0.93) for 
the classification of myocardial infarction.  
 
Lowering the diagnostic threshold from 200 to 50 ng/L identified an additional 257 patients 
with type 1 myocardial infarction, 239 patients with type 2 myocardial infarction and 335 
patients with myocardial injury: a 22%, 56% and 64% increase respectively (P<0.001). The 
incidence rate for type 1, type 2 myocardial infarction, and myocardial injury increased with 
age (Figure 1).  
 
Clinical characteristics 
Compared to type 1 myocardial infarction, patients with type 2 myocardial infarction or 
myocardial injury were older, had worse renal function and were more likely to be female 
(Table 1). Ninety seven percent of patients with type 1 myocardial infarction had a physician 
diagnosis of acute coronary syndrome, whereas patients with type 2 myocardial infarction or 
myocardial injury had a wide range of alternative clinical diagnoses (eFigure 2). Majority of 
patients with type 2 myocardial infarction presented with chest pain and had a clear 
alternative primary diagnosis. Patients with myocardial injury were more likely to present 
with dyspnea, syncope, or confusion. The most common conditions predisposing to type 2 
myocardial infarction or myocardial injury were tachyarrhythmia, heart failure and respiratory 
disorders. (Table 1).  
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Peak troponin concentrations were higher in patients with type 1 myocardial infarction at 
2,420 ng/L compared to 140 ng/L and 130 ng/L in patients with type 2 myocardial infarction 
and myocardial injury respectively. The majority of patients had a ≥20% change in troponin 
concentration on serial sampling and this was similar across all groups. Patients with type 1 
myocardial infarction were more likely to have ST-segment elevation on the 
electrocardiogram, whereas ST-segment depression and T-wave inversion were more 
common in patients with type 2 myocardial infarction and myocardial injury. The clinical 
characteristics of patients with type 1 and type 2 myocardial infarction did not differ between 
the validation and implementation phases (data not shown). 
 
Management during index admission 
Compared to type 1 myocardial infarction, patients with type 2 myocardial infarction or 
myocardial injury were less likely to be referred to cardiology services, undergo in-patient 
coronary angiography and revascularization, and discharged on secondary preventative 
therapies (P<0.01 for all; Table 2). The median duration of hospital stay was double in 
patients with type 2 myocardial infarction (median [IQR]; 7 [2-17] days) and myocardial 
injury (10 [4-23] days) compared to type 1 myocardial infarction (4 [2-7] days; P<0.001) 
(Table 2).  
 
In patients with troponin concentration of 50-199 ng/L and type 1 myocardial infarction, 
lowering the diagnostic threshold increased the number of patients referred for a specialist 
opinion, further investigations and treatments for myocardial infarction (P<0.01 for all; Figure 
2 and eTable 1). Lowering the diagnostic threshold also increased the number of patients with 
type 2 myocardial infarction or myocardial injury referred to the cardiologists for further 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
9 
investigation, although the proportion of patients referred was less than for type 1 myocardial 
infarction, and the use of therapies for myocardial infarction was unchanged.   
 
Clinical outcomes  
Compared to patients with type 1 myocardial infarction, patients with type 2 myocardial 
infarction were more likely to die (16% versus 37%, RR 1.95, 95%CI 1.61-2.37), but less 
likely to suffer from recurrent myocardial infarction (12% versus 6%, RR 0.46, 95%CI 0.31-
0.71; Figure 3). Similar risk ratios were obtained for patients with myocardial injury with a 
higher proportion dead at one year (16% versus 37%, RR 2.36, 95%CI 1.99-2.81) and fewer 
recurrent myocardial infarcts (12% versus 4%, RR 0.29, 95%CI 0.18-0.46). Very similar 
cause specific hazards ratio were seen after ajdusting for age and sex for both recurrent 
myocardial infarction and death (Figure 3).  
 
In patients with troponin concentration of 50-199 ng/L, lowering the diagnostic threshold was 
associated with a reduction in recurrent myocardial infarction (24% versus 12%, RR 0.48, 
95%CI 0.27-0.88) in patients with type 1 myocardial infarction, but not in patients with type 2 
myocardial infarction or myocardial injury (Figure 2 and eTable 1). Similar reductions were 
observed for death and recurrent myocardial infarction in patients with type 1 myocardial 
infarction (31% versus 20%, RR 0.64, 95%CI 0.41-0.99), but no change was observed in 
patients with type 2 myocardial infarction (31% versus 27%, RR 0.87, 95%CI 0.59-1.30) or 
myocardial injury (40% versus 34%; RR 0.84, 95%CI 0.61-1.15).   
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Discussion 
The frequency and clinical implications of type 2 myocardial infarction and myocardial injury 
in clinical practice is uncertain. Here we have systematically evaluated all patients with 
elevated plasma troponin concentrations admitted to a regional cardiac center during the 
validation and implementation of a sensitive troponin assay and have made a number of 
important and novel observations. First, type 2 myocardial infarction or myocardial injury are 
as common as type 1 myocardial infarction in clinical practice irrespective of the threshold for 
diagnosis. The incidence of type 2 myocardial infarction or myocardial injury increases with 
age and is more common than type 1 myocardial infarction in patients ≥75 years of age. 
Second, patients with type 2 myocardial infarction or myocardial injury have worse clinical 
outcomes than patients with type 1 myocardial infarction with 1 in 3 patients dead at one year. 
Third, lowering the diagnostic threshold preferentially increases the number of patients 
identified with type 2 myocardial infarction or myocardial injury. Indeed, for every additional 
patient reclassified as type 1 myocardial infarction, we identified three patients with type 2 
myocardial infarction or myocardial injury. Finally, patients reclassified as type 2 myocardial 
infarction or myocardial injury remained in hospital longer and underwent more cardiac 
investigations but, in contrast to type 1 myocardial infarction, were discharged without 
additional cardiac therapies and clinical outcomes remained poor and unchanged.  
 
The Universal Definition makes a distinction between type 2 myocardial infarction and causes 
of elevations in plasma troponin resulting in myocardial injury, such as renal failure, heart 
failure,11 sepsis12,13 and myopericarditis,14 and defines myocardial infarction, regardless of 
pathobiology, as evidence of myocardial necrosis in the presence of clinical symptoms and 
signs of myocardial ischemia.15,16 However, it is clinically challenging to distinguish between 
patients with type 2 myocardial infarction and myocardial injury because there remains 
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considerable overlap between how these two clinical entities.5,6 The consensus document does 
not provide specific criteria on how to differentiate between these entities in clinical practice 
and our analysis represents one of the first attempts to do so in consecutive hospitalised 
patients. Thus, our frequency data may differ from those of others who may have applied a 
different criteria to define type 1 myocardial infarction and may or may not have had a 
category for myocardial injury. Accordingly, the frequency of type 2 myocardial infarction in 
our study of 20% (429/2,165) was lower than the only previous reports where the frequency 
was 30% (64/701 patients)17 and 26% (144/553 patients)18 in unselected hospitalised patients 
with elevated troponin concentrations. Our analysis is novel in that we distinguish between 
patients with type 2 myocardial infarction and myocardial injury, and differences in 
classification may explain the lower rates of type 2 myocardial infarction in our cohort. 
Perhaps unsurprisingly, type 2 myocardial infarction has been reported to be less frequent (2 
to 5%) in highly selected populations with myocardial infarction from randomised controlled 
trials or registries of patients admitted to cardiac units.4,19,20 Our patients were widely 
distributed across medical and surgical specialties, and it is likely selection bias has 
underestimated the prevelance of type 2 myocardial infarction in these studies.  
 
One of the main strengths of our study is that we identified a group of patients admitted 
during the validation period in whom plasma troponin concentrations of 50-199 ng/L were 
reported as normal. This allowed us to assess the impact of implementation of a sensitive 
troponin assay on the management and clinical outcome of these patients. Lowering the 
diagnostic threshold for myocardial infarction increased the use of appropriate investigations 
and treatments in patients with type 1 myocardial infarction. This was associated with a 
reduction in recurrent myocardial infarction and death consistent with our previous report.7 In 
contrast, there was no improvement in the clinical outcome of patients with type 2 myocardial 
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infarction or myocardial injury despite increased referral to cardiology services and 
subsequent additional invasive and non-invasive investigations. Approximately one third of 
patients with type 2 myocardial infarction were dead at one year. These findings are 
consistent with Saaby et al. who observed mortality rates that were two fold higher in patients 
with type 2 myocardial infarction compared to type 1 myocardial infarction.21 Importantly, 
despite more patients being identified as having type 2 myocardial infarction after lowering 
the diagnostic threshold, the majority of these patients did not receive additional therapies for 
coronary heart disease. This may represent a missed opportunity to improve outcomes and 
further prospective studies are required to define the optimal management of patients with 
type 2 myocardial infarction.  
 
The increased frequency of type 2 myocardial infarction or myocardial injury is likely to be 
even more marked with the development of the next generation high-sensitivity troponin 
assays that will permit further lowering of the diagnostic threshold for myocardial 
infarction.22-24 These assays are likely to identify an even greater and more disproportionate 
number of patients with myocardial injury or type 2 myocardial infarction. However, this 
must not detract from the substantial benefits that high-sensitivity assays will confer for 
diagnosing patients with type 1 myocardial infarction.25,26 This underlines the need to provide 
additional guidance on how to distinguish between myocardial infarction and myocardial 
injury.27   
 
We believe there remains scope for clarification of the diagnostic criteria for type 2 
myocardial infarction and that this is necessary to help clinicians adopt the proposed 
classification. Acute myocardial injury should be the initial diagnosis in all patients with 
troponin elevations due to supply-demand imbalance including those with chest pain or 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
13 
evidence of myocardial ischemia. This would be in keeping with many other organ systems, 
such as acute liver or kidney injury, where similar elevations in tissue enzymes or biomarkers 
confer major prognostic value, but are not disease specific. In our opinion, type 2 myocardial 
infarction should be used exclusively in patients where coronary artery disease has 
contributed to myocardial injury and where there may be opportunities to improve outcomes 
through medical therapy or coronary revascularization. Selection of patients for further 
investigation will depend on the mechanism of myocardial injury and the patient’s probability 
of having coronary artery disease.5 
 
Despite our careful attempts to classify patients, we were reliant on investigations performed 
by attending clinicians. Whilst agreement between our adjudicating cardiologists and internal 
medicine physicians was excellent, we accept that a small proportion of patients with type 2 
myocardial infarction or myocardial injury may have been misclassified. Furthemore, we 
were unable to differentiate between acute and chronic myocardial injury in many patients as 
serial samples were requested at the discretion of the clinical team and were not routinely 
obtained in patients without suspected acute coronary syndrome.  
 
In conclusion, we have demonstrated that type 2 myocardial infarction and myocardial injury 
are now as common as type 1 myocardial infarction in clinical practice. Using a sensitive 
troponin assay, we identified three patients with type 2 myocardial infarction or myocardial 
injury for every patient reclassified as type 1 myocardial infarction. Whilst this was associated 
with better treatment and outcomes in patients with type 1 myocardial infarction, patients 
with type 2 myocardial infarction or myocardial injury underwent more investigations and 
utilized additional cardiac services without altering their poor clinical outcome.  
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Figure Legends 
 
Figure 1. Incidence rate of type 1 myocardial infarction, type 2 myocardial infarction 
and myocardial injury per 100,000 persons in Lothian stratified by age  
The incidence rate was estimated as the number of events during the total 12-month period 
divided by the mid-year population estimates for that age-specific stratum.10 Patients <75 
years had a higher incidence of type 1 than type 2 myocardial infarction or myocardial injury 
(124 versus 60 per 100,000 persons) whereas the reverse was true for patients ≥75 years (750 
versus 1,008 per 100,000 persons).  
 
 
Figure 2. Cumulative incidence of (a) recurrent myocardial infarction and (b) death in 
patients with type 1 myocardial infarction, type 2 myocardial infarction and myocardial 
injury 
Compared to patients with type 1 myocardial infarction, patients with type 2 myocardial 
infarction or myocardial injury were less likely to be readmitted with myocardial infarction, 
but were more likely to die at one year. In comparison to patients with type 1 myocardial 
infarction, more patients with type 2 myocardial infarction (16% versus 31%; HR 1.62, 95% 
CI 1.30-2.04) and myocardial injury (16% versus 37%; HR 1.87, 95% CI 1.52- 2.30) were 
dead, but fewer had recurrent myocardial infarction (12% versus 6%; HR 0.40, 95% CI 0.26-
0.62 and 12% versus 3%; HR 0.24, 95% CI 0.15- 0.40 respectively) at one year. Hazards ratio 
presented after adjustment for age and sex with type 1 myocardial infacrtion as referrent. 
 
Figure 3. Change in the investigation, management and clinical outcomes of patients with 
type 1 myocardial infarction, type 2 myocardial infarction and myocardial injury following 
implementation of a sensitive troponin assay 
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In patients with troponin concentrations of 50-199 ng/L and type 1 myocardial infarction, 
lowering the diagnostic threshold increased referrals for a specialist opinion, further 
investigation and treatments for myocardial infarction (P<0.01 for all). For patients with type 
2 myocardial infarction and myocardial injury similar patterns were seen although the 
absolute magnitude was smaller. In patients with type 1 myocardial infarction, lowering the 
diagnostic threshold was associated with a significant reduction in recurrent myocardial 
infarction (absolute risk reduction 12%, 95% CI 3 to 23%) whereas outcomes in patients with 
type 2 myocardial infarction and myocardial injury remained unchanged.  PCI = percutaneous 
coronary intervention; DAPT = dual anti-platelet therapy. *P<0.05, ** P<0.01, ***P<0.001 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Sensitive troponin assay and classification of myocardial infarction 
ORIGINAL CONTRIBUTION 
 
Sensitive Troponin Assay and 
the Classification of Myocardial Infarction 
 
Anoop SV Shah MD,1* David A McAllister MD,2* Rosamund Mills,1 Kuan Ken Lee,1 
Antonia MD Churchhouse BSc MD,1 Kathryn M Fleming BSc,1 Elizabeth Layden MD, 1 Atul 
Anand MD,1 Omar Fersia MD, 1 Nikhil V Joshi MD,1 Simon Walker DM FRCPath,3 Allan S 
Jaffe MD,4 Keith AA Fox FRCP FESC FMedSci,1 David E Newby FACC FESC FMedSci,1 
Nicholas L Mills MD PhD1 
 
1 BHF Centre for Cardiovascular Science, Edinburgh University, Edinburgh, United Kingdom 
2 Centre for Population Health Sciences, Edinburgh University, Edinburgh, United Kingdom 
3 Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, United Kingdom 
4 Mayo Clinic, Rochester, Minnesota, United States of America  
 
*Both authors have contributed equally 
 
Correspondence and requests for reprints: 
 
Dr Nicholas L Mills 
BHF/University Centre for Cardiovascular Science 
Chancellor’s Building 
Royal Infirmary 
Little France 
Edinburgh 
EH16 4SB 
UNITED KINGDOM 
Tel:    +44 131 242 6517 
Fax:   +44 131 242 6379 
E-mail: nick.mills@ed.ac.uk 
 
 
Support:  British Heart Foundation Intermediate Fellowship (FS/10/024/28266) and 
Clinical Research Fellowship (SS/CH/09/002)  
Relationship with industry: ASVS, NLM and SW have received honoraria for Abbott 
Diagnostics and NLM has acted as a consultant for Beckman-Coultar and Abbott Diagnostics. 
ASJ has consulted for most of the major diagnostic companies. All other authors have no 
conflict of interest or financial disclosures to declare. All authors had access to the data and a 
role in writing the manuscript. 
 
Abstract:   295                  Figures and tables: 5 
Word count:  2,991   References:   25 
Keywords: troponin, myocardial infarction, type 2, outcomes 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 2 
Table 1. Baseline characteristics of patients with type 1 myocardial infarction, type 2 
myocardial infarction and myocardial injury 
  
Type 1 MI Type 2 MI Myocardial injury 
(n=1,171) (n=429) (n=522) 
Age 68 (14) 75 (14) 76 (13) 
Male sex, (%) 709 (61%) 222 (52%) 260 (50%) 
Presenting symptom, n (%)       
Ischaemic chest pain 1,041 (89%) 217 (51%) 0 (0%) 
Dyspnoea 45 (4%) 80 (19%) 172 (33%) 
Collapse/syncope 21 (2%) 31 (7%) 94 (18%) 
Falls 18 (2%) 40 (9%) 86 (17%) 
Confusion 2 (0%) 15 (4%) 23 (4%) 
Palpitations 2 (0%) 4 (1%) 18 (3%) 
Abdominal pain 6 (1%) 6 (1%) 12 (2%) 
Cardiac arrest 14 (1%) 0 (0%) 3 (1%) 
Past medical history, n (%)       
Ischemic heart disease 497 (45%) 191 (45%) 186 (36%) 
Myocardial infarction 231 (24%) 109 (26%) 107 (21%) 
Stroke 92 (8%) 48 (11%) 86 (17%) 
Peripheral vascular disease 85(8%) 29 (7%) 39 (8%) 
Previous PCI 153 (15%) 17 (4%) 23 (5%) 
Previous CABG 62 (6%) 30 (7%) 32 (6%) 
Risk factors, n (%)       
Current smoker 380 (34%) 62 (15%) 73 (14%) 
Hypertension 533 (48%) 254 (59%) 303 (59%) 
Hyperlipidemia 539 (49%) 177 (42%) 202 (39%) 
Diabetes mellitus 185 (17%) 93 (22%) 96 (19%) 
Biochemistry       
Hemoglobin, mg/dL 13.3 (2.0) 12.1 (2.5) 12.0 (2.2) 
Creatinine, mg/dL 1.2 (0.7) 1.5 (1.2) 1.4 (1.4) 
GFR, ml/min 69 (26) 56 (30) 52 (33) 
GFR < 30ml/min, % 89 (8%) 67 (16%) 125 (24%) 
Cholesterol, mg/dL 185 (50) 166 (51) 171 (53) 
Troponin, ng/L 2,420 (270-15,230) 140 (70-660) 130 (60-390) 
Change in troponin ≥ 20% 432 (86%) 41 (65%) 41 (79%) 
Electrocardiography, no (%)       
ST elevation 427 (38%) 40 (10%) 3 (1%) 
ST depression 207 (18%) 152 (36%) 0 (0%) 
T-wave inversion 125 (11%) 97 (23%) 13 (3%) 
Medication on admission, no (%) 
Aspirin 418 (50%) 222 (56%) 244 (54%) 
Clopidogrel 100 (12%) 25 (6%) 26 (6%) 
ß-blockers 257 (31%) 101 (26%) 111 (25%) 
ACE-inhibitors 300 (36%) 136 (34%) 158 (35%) 
Statins 384 (47%) 156 (40%) 191 (42%) 
Warfarin 35 (4%) 38 (10%) 52 (12%) 
Proton pump inhibitors 188 (24%) 127 (33%) 135 (30%) 
Values are mean (standard deviation), median  (interquartile range) and counts (%). Abbreviations: PCI – Percutaneous Coronary Intervention, CABG – 
Coronary Artery Bypass Grafting, TIMI – Thrombolysis in Myocardial Infarction, GFR = Glomerular Filtration Rate, ACE – Angiotensin Converting 
Enzyme. Conversion factor to SI Units as follows: Hemoglobin = 10, Creatinine = 88.4, Cholesterol = 0.0259). 
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 Table 2. Management and outcomes of patients with type 1 myocardial infarction, type 2 myocardial infarction and myocardial injury 
  
Type 1 MI 
(n = 1,171) 
Type 2 MI 
(n = 429) 
Myocardial injury 
(n = 522)  
P-Value/ RR 
Type 1 versus Type 2  
 
P-Value / RR 
Type 2 versus  
myocardial injury 
Management, n (%), median (IQR) 
     
Cardiology referral 1,004 (87%) 181 (43%) 146 (29%) <.001 <.001 
Length of stay, median days (IQR) 4 (2-7) 7 (2 – 17) 10 (4 – 23) <.001 <.001 
Investigations, n (%)            
Echocardiography 340 (30%) 122 (29%) 117 (23%) 0.535 0.042 
Exercise tolerance test 29 (3%) 1 (0%) 0 (0%) 0.003 0.451 
Angiography 744 (65%) 31 (7%) 19 (4%) <.001 0.012 
Coronary revascularization, n (%)     
PCI 564 (49%) 1 (0%) 3 (1%) <.001 0.632 
CABG 56 (5%) 3 (1%) 3 (1%) <.001 0.999 
Medications on discharge, n (%)     
Aspirin 910 (90%) 166 (49%) 192 (49%) <.001 0.835 
Clopidogrel 831 (80%) 48 (14%) 38 (9%) <.001 0.052 
Dual anti-platelet therapy 789 (76%) 26 (7%) 26 (6%) <.001 0.547 
ß-blockers 660 (63%) 124 (36%) 114 (28%) <.001 0.02 
ACE-inhibitors 735 (71%) 135 (39%) 159 (39%) <.001 0.999 
Statins 884 (85%) 152 (44%) 190 (46%) <.001 0.442 
Warfarin 35 (3%) 52 (15%) 61 (15%) <.001 0.965 
Proton pump inhibitors 304 (29%) 135 (39%) 150 (37%) 0.001 0.508 
Outcomes, n (%)           
Recurrent MI a 141 (12%) 24 (6%) 18 (3%) 0.46 (0.31 – 0.71) 0.62 (0.34 – 1.12) 
Death 187 (16%) 134 (31%) 193 (37%) 1.95 (1.61 – 2.37) 1.19 (0.99 – 1.42) 
Recurrent MI/death 280 (24%) 144 (34%) 203 (39%) 1.40 (1.19 – 1.66) 1.16 (0.98 – 1.38) 
Gastrointestinal bleeding b 20 (2%) 11 (3%) 7 (1%) 1.50 (0.73 – 3.11) 0.52 (0.21 – 1.34) 
Strokec 24 (2%) 11 (3%) 22 (4%) 1.25 (0.61 – 2.53) 1.64 (0.81 – 3.35) 
Coronary revascularizationd 95 (8%) 5 (1%) 5 (1%) 0.14 (0.06 – 0.35) 0.82 (0.24 – 2.82) 
a Recurrent type 1 myocardial infarction.  b Includes type II – V bleeding as defined in the recent consensus statement.20 c Defined as stroke by the attending physician. d Coronary revascularization includes both percutaneous coronary 
intervention and coronary artery bypass grafting. e Type 1 myocardial infarction as referent. f Type 2 myocardial infarction as referent.  
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Clinical significance of the manuscript 
 
 
• Lowering the diagnostic threshold for troponin preferentially increases the 
number of patients identified with type 2 myocardial infarction or myocardial 
injury.  
 
• Patients reclassified as type 2 myocardial infarction or myocardial injury 
remained in hospital for longer and were more likely to undergo cardiac 
investigations but, in contrast to type 1 myocardial infarction, were discharged 
without additional cardiac therapies and clinical outcomes remained poor and 
unchanged 
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eFigure 1. CONSORT diagram of study population stratified by infarct type and 
study phase. Consecutive patients with plasma troponin I (TnI) concentrations ≥50 
ng/L were identified irrespective of clinical presentation during the validation (1st 
February 2008 to 31st July 2008) and implementation (1st February 2009 to 31st July 
2009) of a contemporary sensitive troponin I assay (n=2,929). Exclusion criteria were 
limited to patients admitted for elective non-emergency procedures, patients who 
were resident outwith Lothian, and patients with incomplete hospital records. The 
remaining 2,165 patients were classified as type 1 to type 5 myocardial infarction or 
myocardial injury. Whilst plasma troponin was measured using a reformulated 
sensitive assay throughout both phases, only concentrations above a diagnostic 
threshold of 200 ng/L were reported in the validation phase, whilst concentrations 
above a revised diagnostic threshold of 50 ng/mL were reported during the 
implementation phase.  
 
eFigure 2. Primary diagnosis of patients with type 2 myocardial infarction and 
myocardial injury. Patients classified as (a) type 2 myocardial infarction or (b) 
myocardial injury were a heterogeneous group presenting to a wide range of medical 
and surgical specialties. Most patients with type 2 myocardial infarction had a cardiac 
or respiratory diagnosis with heart failure and arrhythmias the most common cause of 
elevated troponin concentrations.  
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eFigure 1: CONSORT diagram 
 
Study population 
 (n= 2,929) 
TnI ≥ 50 ng/ml  
Exclusions (n = 764) 
Elective procedures (n = 121) 
Resident out with Lothian (n = 297) 
Missing / incomplete hospital records (n=346) 
Patients included = 2,165 
Type 1 MI – 1,171 patients (54%) 
Type 2 MI – 429 patients (20%) 
 Myocardial injury –  522 patients (24%) 
Type 3 MI – 12 patients (0.5%) 
Type 4 MI – 21 patients (1%) 
Type 5 MI – 10 patients (0.5%) 
During the validation phase, only 
concentrations above diagnostic 
threshold of ≥200 ng/L were 
reported to clinicians  
Implementation 
Phase 
(n = 920) 
Validation 
Phase  
(n = 1,202) 
Type 2 MI 
(n = 236)  
Type 1 MI 
(n = 620) 
Myocardial 
injury 
(n = 346)  
Type 2 MI 
(n = 193)  
Type 1 MI 
(n = 551) 
Myocardial 
injury 
(n = 176)  
TnI  
50 – 199 ng/L 
(n = 136) 
TnI  
≥ 200 ng/L 
(n = 484) 
TnI  
50 – 199 ng/L 
(n = 125) 
TnI  
≥ 200 ng/L 
(n = 111) 
TnI  
50 – 199 ng/L 
(n = 237) 
TnI  
≥ 200 ng/L 
(n = 109) 
TnI  
50 – 199 ng/L 
(n = 121) 
TnI  
≥ 200 ng/L 
(n = 430) 
TnI  
50 – 199 ng/L 
(n = 114) 
TnI  
≥ 200 ng/L 
(n = 79) 
TnI  
50 – 199 ng/L 
(n = 98) 
TnI  
≥ 200 ng/L 
(n = 78) 
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eTable 1: Clinical investigations, management and outcomes in patients with troponin concentration between 50 and 199 ng/L in patients with type 1 myocardial infarction, type 2 myocardial infarction and myocardial injury 
 
 
 
Validation  Implementation P-value/Relative  Validation Implementation P-value/ Relative  Validation Implementation P-value/ Relative  
  (n = 136) (n = 121) Risk e (95% CI) (n = 125) (n = 114)   Risk e (95% CI) (n = 237) (n = 98)   Risk e (95% CI) 
Cardiology referral 67 (50%) 96 (83%) <0.001 31 (26%) 53 (48%) 0.001 40 (18%) 27 (28%) 0.043 
Investigations, n (%) 
         
Echocardiography 6 (4%) 16 (13%) 0.014 19 (15%) 31 (27%) 0.023 28 (12%) 23 (24%) 0.007 
Exercise tolerance test 6 (4%) 3 (2%) >0.99 1 (1%) 0 (0%) 0.999 0 (0%) 0 (0%) - 
Angiography 36 (27%) 60 (52%) <0.001 3 (3%) 10 (9%) 0.032 2 (1%) 5 (5%) 0.025 
Coronary revascularisation, n (%)           
PCI 19 (14%) 34 (30%) 0.005 1 (1%) 0 (0%) 0.999 0 (0%) 0 (0%) - 
CABG 7 (5%) 3 (3%) 1.00 1 (1%) 1 (1%) 0.999 0 (0%) 0 (0%) 0.376 
Medications on discharge, n (%) 
         
Aspirin 91 (73%) 95 (85%) 0.038 52 (47%) 53 (54%) 0.366 92 (47%) 35 (43%) 0.595 
Clopidogrel 53 (43%) 75 (63%) 0.002 10 (9%) 11 (11%) 0.628 8 (4%) 7 (9%) 0.124 
Dual anti-platelet therapy 47 (38%) 65 (58%) 0.003 6 (6%) 5 (5%) 0.896 4 (2%) 3 (4%) 0.418 
ß-blockers 68 (55%) 67 (60%) 0.511 37 (34%) 37 (37%) 0.573 50 (25%) 23 (28%) 0.572 
ACE-inhibitors 64 (52%) 76 (68%) 0.017 39 (36%) 45 (46%) 0.141 70 (35%) 38 (47%) 0.072 
Statins 82 (57%) 85 (76%) 0.150 42 (38%) 49 (50%) 0.100 95 (48%) 31 (38%) 0.130 
Warfarin 9 (5%) 7 (6%) 0.770 18 (17%) 17 (17%) 0.923 26 (13%) 15 (19%) 0.263 
Proton pump inhibitors 23 (23%) 51 (46%) 0.001 41 (38%) 33 (33%) 0.488 60 (31%) 30 (37%) 0.299 
12-month outcomes, n (%) 
         
Recurrent MI a 33 (24%) 14 (12%) 0.48 (0.27 - 0.88) 10 (8%) 8 (7%) 0.88 (0.36 – 2.14) 13 (6%) 3 (3%) 0.56 (0.19 - 1.92) 
Death 19 (14%) 12 (10%) 0.71 (0.36 - 1.40) 34 (27%) 29 (25%) 0.94 (0.61 - 1.43) 86 (36%) 33 (34%) 0.93 (0.67 - 1.28) 
Recurrent MI/death 42 (31%) 24 (20%) 0.64 (0.41 - 0.99) 39 (31%) 31 (27%) 0.87 (0.59 - 1.30) 95 (40%) 33 (34%) 0.84 (0.61 – 1.15) 
Gastrointestinal bleeding b 2 (2%) 3 (3%) 1.67 (0.29 - 9.92) 2 (2%) 2 (2%) 1.10 (0.16 - 7.66) 3 (1%) 4 (4%) 3.22 (0.73 – 14.14) 
Stroke c 2 (2%) 1 (1%) 0.56 (0.05 – 6.12) 2 (2%) 3 (3%) 1.10 (0.23 – 5.32) 13 (6%) 3 (3%) 0.56 (0.16 - 1.92) 
Coronary revascularizationd 17 (13%) 15 (12%) 0.99 (0.51 - 1.90) 1 (1%) 1 (1%) 1.10 (0.07 - 17.32) 4 (2%) 0 (0%) - 
 
Values are mean (standard deviation)  median  (interquartile range) and counts (%). Abbreviations: ACE – angiotensin converting enzyme, PCI – Percutaneous Coronary Intervention, CABG – Coronary Artery Bypass Grafting. a Recurrent type 1 
myocardial infarction.  b Includes type 2 – V bleeding as defined in the recent consensus statement.20  cDefined as stroke by the attending physician.  dCoronary revascularization includes both percutaneous coronary intervention and coronary artery 
bypass grafting. eRelative risks comparing implementation phase with validation phase as the reference group 
Type 1 myocardial infarction Type 2 myocardial infarction Myocardial injury 
